



Volume 3, Issue 4
April 2024

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- Meningococcal conjugate ACWY (MEQUADFI)
- Sodium Chloride tablets
- Cholecalciferol capsules
- Lactobacillus tablets
- Paraffin wax topical
- Aluminum hydroxide/magnesium carbonate chewable tablet
- Magnesium oxide tablet
- Camphor/menthol gel
- Chlorhexidine gluconate wipes
- Lemon/glycerin swabs
- Sitagliptin (ZITUVIO)

Drugs Added to the VA National Formulary WITH Prior Authorization

- Yellow Fever vaccine (Sanofi)
- Eltrombopag Choline (ALVAIZ)
- DaxibotulinumtoxinA (DAXXIFY)

Drugs Not Added to the VA National Formulary

- Pentavalent meningococcal vaccine (PENBRAYA)
- Etrasimod (VELSIPITY) tablets
- Adalimumab-ryvk (SIMLANDI) SC Injection
- Resmetirom (REZDIFFRA) tablets
- Belumosudil (REZUROCK)

Formulary Drugs with Prior Authorization Removed

- Thickening agents for patients with dysphagia
- Zoledronic acid (RECLAST)
- Remdesivir (VEKLURY)

Drugs Removed from the VA National Formulary

- Phenylephrine Oral Tablets
- Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate (OsmoPrep, Visicol) Tablets (products discontinued)
- Sodium Phenylbutyrate/Taurursodiol (RELYVRIO) (product discontinued)

Other Announcements

- Lasmiditan (REYVOW) Criteria for Use revised
- Semaglutide (WEGOVY) Criteria for Use revised
- Ketamine for Acute Pain in VHA ED or UCC guidance document updated
- Revfenacin_YUPELRI_Monograph revised